Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand ¹⁸F-AH111585 in Breast Cancer Patients

Abstract

18F-AH111585 designed to bind the alpha v beta3 integrin is safe, metabolically stable, and retained in tumor tissues and detects breast cancer lesions by PET in most anatomic sites.